Provectus Biopharmaceuticals, Inc. (PVCT)
Stock Price:
$0.0615 USD
0.0000 (0.00%)
Updated December 2, 4:00 PM EST - Market closed
Key Info
| Market Cap |
24.66M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-6.56M |
| Shares Out |
393.50M |
| EPS (ttm) |
-0.02 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 2 |
| Last Price |
$0.0615 |
| Previous Close |
$0.0615 |
| Change ($) |
0.0000 |
| Change (%) |
0.00% |
| Day's Open |
- |
| Day's Range |
0.0600 - 0.0000 |
| Day's Volume |
0 |
| 52-Week Range |
0.0000 - 0.0000 |
More Stats
| Market Cap |
24.66M |
| Enterprise Value |
47.15M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
393.50M |
| Float |
n/a |
| EPS (basic) |
-0.01 |
| EPS (diluted) |
-0.02 |
| FCF / Share |
-0.01 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.82M |
| Short Ratio |
0.47 |
| Short % of Float |
n/a |
| Beta |
0.85 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.44 |
| Revenue |
n/a |
| Operating Income |
-4.98M |
| Net Income |
-6.56M |
| Free Cash Flow |
-4.27M |
| Net Cash |
-22.49M |
| Net Cash / Share |
-0.06 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-210.69% |
| ROE |
n/a |
| ROIC |
-84.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
3.50
Current: $0.0615
High
3.50
Target: 3.50
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -6.30 | -8.05 | -13.32 | -24.95 | -24.65 | -16.81 | -13.03 | -14.34 | -21.44 | -20.69 |
| Net Income | -6.92 | -8.15 | -13.52 | -24.43 | -24.50 | -10.24 | -27.70 | -12.57 | -19.43 | -18.55 |
| Shares Outstanding | 387 | 382 | 369 | 234 | 196 | 176 | 132 | 113 | 106 | 78.82 |
| Earnings Per Share | -0.02 | -0.02 | -0.04 | -0.12 | -0.13 | -0.06 | -0.22 | -0.11 | -0.19 | -0.37 |
| Operating Cash Flow | -6.19 | -5.20 | -10.35 | -21.94 | -17.41 | -13.85 | -9.89 | -11.26 | -17.20 | -13.73 |
| Capital Expenditures | - | - | -0.03 | - | -0.01 | -0.07 | -0.01 | -0.02 | -0.01 | - |
| Free Cash Flow | -6.19 | -5.20 | -10.38 | -21.94 | -17.42 | -13.92 | -9.90 | -11.27 | -17.21 | -13.73 |
| Cash & Equivalents | 0.59 | 0.05 | 0.11 | 1.17 | 14.18 | 17.39 | 15.70 | 1.22 | 7.71 | 8.09 |
| Total Debt | 20.37 | 13.93 | 9.46 | - | - | - | - | - | - | - |
| Net Cash / Debt | -19.78 | -13.88 | -9.35 | 1.17 | 14.18 | 17.39 | 15.70 | 1.22 | 7.71 | 8.09 |
| Assets | 1.48 | 1.99 | 3.44 | 5.61 | 20.44 | 26.18 | 20.01 | 6.20 | 13.35 | 14.40 |
| Liabilities | 25.55 | 19.41 | 13.46 | 2.14 | 4.12 | 0.99 | 13.38 | 1.81 | 3.33 | 3.70 |
| Book Value | -24.07 | -17.42 | -10.02 | 3.47 | 16.32 | 25.19 | 6.63 | 4.39 | 10.02 | 10.70 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Provectus Biopharmaceuticals, Inc. |
| Country |
United States |
| Employees |
2 |
Stock Information
| Ticker Symbol |
PVCT |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: PVCT |
Description
Provectus Biopharmaceuticals, a clinical-stage biotechnology company, engages in developing drugs based on halogenated xanthenes for oncology, hematology, and dermatology indications. Its prescription drug candidates include PV-10, which is in Phase Ib/II study for metastatic melanoma; Phase I study for hepatocellular carcinoma and other solid tumors metastatic to the liver; and non-clinical assessment of pediatric cancer tumor cell. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.